Press release content from Business Wire. The AP news staff was not involved in its creation.
Mike Nally to Leave Merck; Frank Clyburn to Lead All Merck Human Health
March 17, 2021 GMT
KENILWORTH, N.J. (BUSINESS WIRE) Mar 17, 2021
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Michael T. Nally, chief marketing officer, Human Health, will leave the company at the end of March, and Frank Clyburn, chief commercial officer, Human Health, will become president, Human Health and lead all Human Health commercial and marketing for the company. Nally is leaving Merck for a leadership opportunity with another company.
By Reuters Staff
1 Min Read
FILE PHOTO: The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid
(Reuters) - Merck & Co said on Wednesday its Chief Marketing Officer Michael Nally will leave the company, the second top executive to do so after the drugmaker announced last month its Chief Executive Officer Kenneth Frazier will step down in June.
Nally, who is also the executive vice president of the drugmaker’s Human Health division, will leave the company at the end of March to pursue other opportunities, Merck said.
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience. Necessary
Feb 4, 2021 8:10am
Ken Frazier, the only Black CEO of Big Pharma company, will retire as Merck & Co.’s chief executive June 30. (PhRMA)
The only Black CEO of a Big Pharma company and one who s spoken out about racial injustice and pandemic promises is now retiring.
Ken Frazier, who has been Merck & Co.’s chief executive since 2011, will retire June 30, the New Jersey pharma said Thursday. He will continue to serve as executive chairman for a transition period that’s yet to be determined.
Robert Davis, currently Merck’s chief financial officer, will take the reins.
Frazier joined Merck in 1992, and, during his long tenure as the company’s general counsel, he led the litigation around top-selling painkiller Vioxx, now withdrawn for safety reasons. As CEO, he’s credited for churning out enviable growth at Merck with the launches of innovative medicines, most notably PD-1 inhibitor Keytruda.